Cargando…
An integrated platform approach enables discovery of potent, selective and ligand-competitive cyclic peptides targeting the GIP receptor
In any drug discovery effort, the identification of hits for further optimisation is of crucial importance. For peptide therapeutics, display technologies such as mRNA display have emerged as powerful methodologies to identify these desired de novo hit ligands against targets of interest. The divers...
Autores principales: | Bhushan, Bhaskar, Granata, Daniele, Kaas, Christian S., Kasimova, Marina A., Ren, Qiansheng, Cramer, Christian N., White, Mark D., Hansen, Ann Maria K., Fledelius, Christian, Invernizzi, Gaetano, Deibler, Kristine, Coleman, Oliver D., Zhao, Xin, Qu, Xinping, Liu, Haimo, Zurmühl, Silvana S., Kodra, Janos T., Kawamura, Akane, Münzel, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926291/ https://www.ncbi.nlm.nih.gov/pubmed/35414877 http://dx.doi.org/10.1039/d1sc06844j |
Ejemplares similares
-
GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010) -
GIP1 and GIP2 Contribute to the Maintenance of Genome Stability at the Nuclear Periphery
por: Singh, Gaurav, et al.
Publicado: (2022) -
Mechanism of Cancer Growth Suppression of Alpha-Fetoprotein Derived Growth Inhibitory Peptides (GIP): Comparison of GIP-34 versus GIP-8 (AFPep). Updates and Prospects
por: Mizejewski, Gerald J.
Publicado: (2011) -
Species‐specific action of (Pro3)GIP – a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
por: Sparre‐Ulrich, A H, et al.
Publicado: (2015) -
Vaccination against GIP for the Treatment of Obesity
por: Fulurija, Alma, et al.
Publicado: (2008)